DOCSLIB.ORG

Message from the President

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Message from the President DermNewsletter of the American OsteopathicLine College of Dermatology Winter 2015/16 Vol. 31, No. 3 Message from the President Greetings from Houston, Texas! As President of the AOCD, I welcome you to another edition of DermLine. I want to express my appreciation to Dr. Rick Lin, our Immediate Past President for his tireless efforts on behalf of the College. His friendship and his willingness to continue participating in a meaningful way will only make this year successful. I appreciated our time together in Orlando on a number of different levels. First, the friendships that continue and the opportunity to develop new friendships and relationships are vital to our personal growth and development. Secondly, hearing new ways of doing things, discussing similar challenges, and hearing solutions to many old challenges was powerful. Finally, I believe there are no words to describe how special Orlando was personally to me. The attendees were so very caring! There is, inherent in this great organization, a camaraderie blended with the desire to help others. The kindnesses shown to me during this conference will linger long in my memory. The year 2016 is upon us. It seems only yesterday I was entering the Kansas City University of Medicine and Biosciences in Kansas City followed by my internship and residency; these are now but distant memories. Soon another cycle will pass. New, excited doctors will emerge and enter residencies in dermatology. As director of the South Texas Dermatology Residency Program in Houston, I have borne witness to fine physicians honing their skills and expanding their knowledge in anticipation of launching their medical careers. We need to be mindful that the future of our organization rests squarely upon the shoulders of these new physicians we train. It is to the great benefit of the AOCD that we serve not only as mentors, but remain active in their development in both practice and science. Our future residents and fellows will find an exciting new development awaits them. The AOA, along with the Accreditation Council for Graduate Medical Education and the American Association of Colleges of Osteopathic Medicine, have agreed to a single accreditation system for graduate medical education programs in the United States. When the new system is fully implemented in July of 2020, the graduates of osteopathic and allopathic medical schools will complete their residency and/or fellowship education in ACGME-accredited programs and demonstrate achievement of common milestones and competencies. No longer will there be a great divide in the practical training of DOs and MDs. Clearly our world is changing! I suppose the greatest morsel I could share with you comes from one of my mentors, “Today, at this moment, we are living in yesterday’s future.” The changes in our practice of dermatology and medicine in general are profound. We spend great swaths of time dealing with electronic medical records and ICD 10. My challenge to you is to pause and remember why you chose medicine, and particularly, why you felt dermatology was to be your specialty. Then use that memory to ensure you look at your patients through that lens tinted with that memory. While we must tend to the busyness In this issue... of EMRs, we must not forget our patients. 2015 Fall Meeting Highlights and Notes I look forward to serving you and the opportunity to meet all of ...pages 6-23 you as you attend our meetings. Foundation for Osteopathic Dermatology Alpesh Desai, DO, FAOCD Update...pages 24-25 President, American Osteopathic College of Dermatology AOCD Thanks 2015 Fall Meeting Sponsors and Exhibitors...pages 26-27 Message from the Past President It has been an amazing seven-year journey. It was approximately seven years ago when I was first elected a Trustee of the AOCD Board of Trustees on a last minute floor nomination. It seemed like a good idea at the time. My practice was growing and I was looking for another challenge. Dr. Jim Young’s installation as the AOCD President had a lasting impression on me as a student member. Later, my own Program Director and role model, Dr. Bill Way, became the President. My admiration for the leaders of the College paved the way for me to aspire for a higher office beyond Trustee. I also have to confess the aspiration was not consistent throughout. After I was accepted into a residency program, a certain amount of complacency set in. After three years of being a dermatology resident, the excitement slowly started to fade. It’s mandatory to attend the Presidential Banquet, which is a long night. I remember thinking that I couldn’t wait for it to be over so I could find out where Dr. Shino Bay was going to party that night. He always seemed to know where the best parties were. Throughout my years as a Trustee and officer of the AOCD BOD, there were many discussions and disagreements among the Board members. Discussions can get heated at times, resulting in hurt feelings and bruised egos. Occasionally, the issues discussed can be very stressful. Sometimes, I didn’t even know if everything I was doing as an AOCD officer was making any difference. I was not sure if it was all worth it. During the last few years leading up to be the presidency, I gradually understood the value of what I was doing. When I attended the American Academy of Dermatology (AAD) Gala and the Mohs Surgery Summit on behalf of the AOCD, I met with the upper echelon of leaders within the AAD. These wonderful leaders of organized dermatology welcomed me to the table for discussions and listened to what I had to say. I realized the reason why I was being treated with respect by these amazing leaders of dermatology is not because Rick Lin is awesome. After all, I am just a country doc practicing in a border town. I was being treated with respect because of who I was representing. Because the members of this College empowered me to represent them, I was speaking with other leaders on equal terms. As the AOCD President, it was no longer just about me anymore. It was, and is, about honoring all the College leaders before me and paving the way for the leaders after me. During the past seven years, I have learned to respect the office and our College. Everything we do, whether it’s the long drawn out Board of Trustees and Business meetings or the President Celebration, it’s about paying homage to all the past and present AOCD members and leaders. It is not just a bunch of us old guys patting each other on the back. Through everyone’s dedication, there exists this institution that provided me the opportunity to become the dermatologist I am today. The AOCD has enabled me to do what I love every day and provide for my family just as it has done for countless other AOCD members. I share my thoughts on this because I would like to encourage all of our younger members and residents to always keep an appreciation and admiration for this College, and to have the aspiration to be part of the AOCD leadership. And to one day, contribute your own energy and talent for the betterment of the College. My seven-year journey to the end of this presidency, of course, has not occurred without personal sacrifice. I have traveled frequently for the AOCD, leaving my wife at home to stay with our three young daughters. I am thankful to my wife for allowing me to sacrifice some family time to fulfill my duty to the College. I also want to mention my mother. Without her, I would not have been able to achieve my dream of being a dermatologist. She has been a role model to me and has instilled in me the values and work ethic of striving to be the best that I can be. I am forever thankful to her for everything. Page 2 To round up this year, I would like to thank Marsha and the AOCD staff for a year of hard work. I also want to thank my Board members for making this a memorable year for me. There are many changes coming our way and we are sailing in uncharted water. During the next five years, the very mission and essence of the AOCD will be tested. Our relevance will be evaluated. Without careful planning and foresight, we may be deemed obsolete. The Accreditation Council for Graduate Medical Education (ACGME) is slated to take over the AOCD’s role in graduate medical education. There are many misunderstandings, even within our membership, about the implications of this merger. Some of our members believe the merger will confer ACGME or MD board certification on us, and with that automatic AAD fellowship status. Nothing is further from the truth. The ACGME merger will leave us to be the group that is left behind. All of us with AOBD board certification now and in the future, will rely solely on the AOBD for future recertification. At this point, we are not eligible for recertification by the American Board of Dermatology. With the ACGME merger, we will likely see the AOCD become a much smaller organization in the course of the next five to 10 years. The current pipeline of 50 AOCD residents every year may not be relying on the College for continuing medical education credit IF the future osteopathic dermatology residents choose not to take the DO board examination. Consequently, the growth of the AOCD may be stunted. As an organization, we will need to re-invent ourselves and modify our vision to ensure our future survival.
Load more

Recommended publications
  • A Case of Schnitzler's Syndrome Without Monoclonal Gammopathy
    Case Report Yonsei Med J 2018 Jan;59(1):154-157 https://doi.org/10.3349/ymj.2018.59.1.154 pISSN: 0513-5796 · eISSN: 1976-2437 A Case of Schnitzler’s Syndrome without Monoclonal Gammopathy-Associated Chronic Urticaria Treated with Anakinra Min Joo Ahn, Ji Eun Yu, Jiung Jeong, Da Woon Sim, and Young-Il Koh Department of Internal Medicine, Chonnam National University Medical School, Gwangju, Korea. Chronic urticaria may often be associated with interleukin (IL)-1-mediated autoinflammatory disease, which should be suspect- ed if systemic inflammation signs are present. Here, we report a case of Schnitzler’s syndrome without monoclonal gammopathy treated successfully with the IL-1 receptor antagonist anakinra. A 69-year-old man suffered from a pruritic urticarial rash for 12 years. It became aggravated episodically and was accompanied by high fever, arthralgia, leukocytosis, and an elevated C-reactive protein and erythrocyte sedimentation rate. The episodes each lasted for over one week. Neutrophilic and eosinophilic inflam- mation was found on skin biopsy. However, serum and urine electrophoresis showed no evidence of monoclonal gammopathy. The cutaneous lesions were unresponsive to various kinds of anti-histamines, systemic glucocorticoids, colchicine, cyclosporine, dapsone, and methotrexate, which were administered over a span of 3 years immediately preceding successful treatment. A dra- matic response, however, was observed after a daily administration of anakinra. This observation suggests that the correct diag- nosis of this case is Schnitzler’s syndrome without monoclonal gammopathy. For an adult patient with refractory chronic urticar- ia and systemic inflammation, Schnitzler’s syndrome could be considered as a possible differential diagnosis.
    [Show full text]
  • SUPPLEMENTARY TABLE 1. Search Strategy to Identify Recombinant
    SUPPLEMENTARY TABLE 1. Search strategy to identify recombinant zoster vaccine (RZV) reports of selected pre-specified outcomes in the Vaccine Adverse Events Reporting System (VAERS) — United States, October 2017–June 2018 Search strategy to identify pre-specified outcomes: Includes MedDRA Preferred Terms, MedDRA System Organ Class Pre-specified outcomes (SOC) groupings, text string searches, or VAERS check boxes Herpes zoster herpes zoster, vaccination failure, vaccine breakthrough infection, Post-herpetic neuralgia post herpetic neuralgia, trigeminal neuralgia, neuralgia Autoimmune disorders cell-mediated immune deficiency, cholangitis, colitis ulcerative, Crohn’s disease, Henoch-Schonlein purpura, Henoch-Schonlein purpura nephritis, immune-mediated adverse reaction, Kawasaki disease, , Raynaud’s phenomenon, Stevens-Johnson syndrome, type III immune complex mediated reaction, acute haemorrhagic colitis ulcerative, cholecystocholangitis, thromboangiitis obliterans, autoimmune myocarditis, autoimmune pericarditis, myocarditis post infection, postpericardiotomy syndrome, alopecia areata, autoimmune dermatitis, benign familial pemphigus, dermatitis herpetiformis, granulomatous dermatitis, herpes gestationis, interstitial granulomatous dermatitis, juvenile psoriatic arthritis, lichen planus, lichen sclerosus, linear IgA disease, palisaded neutrophilic granulomatous dermatitis, paraneoplastic pemphigus, pemphigoid, pemphigus, pityriasis lichenoides et varioliformis acuta, psoriasis, psoriatic arthropathy, pyoderma gangrenosum, pyogenic sterile
    [Show full text]
  • A Case of Stevens-Johnson Syndrome Probably Induced by Herbal Medicine
    Brief Report https://doi.org/10.5021/ad.2018.30.4.481 A Case of Stevens-Johnson Syndrome Probably Induced by Herbal Medicine Ji Hong Lim, Sang Hyun Cho, Jeong Deuk Lee, Hei Sung Kim Department of Dermatology, The Catholic University of Korea, Incheon St. Mary’s Hospital, Seoul, Korea Dear Editor: topathological findings were sub-epidermal split with ex- Stevens-Johnson syndrome (SJS) is a life-threatening skin tensive epidermal necrosis (Fig. 2). The direct immuno- reaction characterized by extensive epidermal detach- fluorescence findings were negative. Days after the skin ment1. Drugs, especially sulfa drugs, anti-epileptics, and biopsy, the vesicles and bullae began to fuse, rapidly pro- antibiotics, are the most common causes1, but recently, gressing into skin erosion and denudation. The mucous SJS associated with herbal medication has been reported2. membranes of the mouth and conjunctiva were also Herein, we report a case of SJS probably induced by herb- affected. Epidermal detachment was seen in less than 10% al medicine. We received the patient’s consent form about of the body surface area and the Nikolsky sign was publishing all photographic materials. The study protocol present. The patient answered that there has been no was approved by the Institutional Review Board of change in his routine medication for the past 3 years, but Incheon St. Mary’s Hospital, The Catholic University of mentioned that he started on herbal medication a month Korea (IRB no. OC17ZESI0049). ago. The herbal medication was said to contain deer ant- A 77-year-old man presented with a sudden onset of bul- lers, ginseng, camphor etc.
    [Show full text]
  • Images of the Month 1: Schnitzler Syndrome
    Clinical Medicine 2020 Vol 20, No 2: 229–30 IMAGES OF THE MONTH I m a g e s o f t h e m o n t h 1 : Schnitzler syndrome: an acquired autoinflammatory syndrome Authors: E v a n g e l i a Z a m p e l i , A L e o n i d a s M a r i n o s B a n d S t a m a t i s J K a r a k a t s a n i sC Fig 1. a) A maculopapular urticarial rash on the patient’s trunk and arms. b) Skin biopsy (haematoxylin and eosin stain, 100× magnifi cation) oedema of the dermis, vascular dilatation, presence of scattered polymorphs (neutrophils and eosinophils) and a slight perivascular T-cell (CD3+) lymphocytic infi ltrate, fi ndings indicative of urticarial neutrophilic dermatosis. c) Pelvic X-ray showed juxta-articular sclerosis of the ilium, adjacent to the sacroiliac joints symmetrically. d) Bone scintigraphy revealed increased radioactive tracer concentration over the painful bony sites (the pelvic bones and the upper part of the right femur). e) Computed tomography-guided bone biopsy from the right ilium showed increased bony thickness overall / osteosclerosis (haematoxylin and eosin stain, 40× magnifi cation). KEYWORDS: Autoinfl ammatory diseases , periodic fever syndromes , joints, pelvic bones and right femur. Laboratory testing showed Schnitzler syndrome , neutrophilic dermatosis , monoclonal mildly elevated white blood cells (12.9 ϫ10 9 /L) and acute-phase gammopathy reactants (C-reactive protein 17.4 mg/L (normal range <5 mg/L) and erythrocyte sedimentation rate 64 mm/h) and a monoclonal immunoglobulin (IgM) kappa band.
    [Show full text]
  • The Schnitzler Syndrome. Dan Lipsker
    The Schnitzler syndrome. Dan Lipsker To cite this version: Dan Lipsker. The Schnitzler syndrome.. Orphanet Journal of Rare Diseases, BioMed Central, 2010, 5 (1), pp.38. 10.1186/1750-1172-5-38. inserm-00663708 HAL Id: inserm-00663708 https://www.hal.inserm.fr/inserm-00663708 Submitted on 27 Jan 2012 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Lipsker Orphanet Journal of Rare Diseases 2010, 5:38 http://www.ojrd.com/content/5/1/38 REVIEW Open Access The Schnitzler syndrome Dan Lipsker Abstract The Schnitzler syndrome is a rare and underdiagnosed entity which is considered today as being a paradigm of an acquired/late onset auto-inflammatory disease. It associates a chronic urticarial skin rash, corresponding from the clinico-pathological viewpoint to a neutrophilic urticarial dermatosis, a monoclonal IgM component and at least 2 of the following signs: fever, joint and/or bone pain, enlarged lymph nodes, spleen and/or liver, increased ESR, increased neutrophil count, abnormal bone imaging findings. It is a chronic disease with only one known case of spontaneous remission. Except of the severe alteration of quality of life related mainly to the rash, fever and pain, complications include severe inflammatory anemia and AA amyloidosis.
    [Show full text]
  • Schnitzler Syndrome: a Case Report and Review of Literature
    Brief Report zepine-induced severe cutaneous adverse drug reactions. J S343-S345. Eur Acad Dermatol Venereol 2013;27:356-364. 5. Lim YL, Thirumoorthy T. Serious cutaneous adverse 4. Yoon J, Oh CW, Kim CY. Stevens-johnson syndrome reactions to traditional Chinese medicines. Singapore Med J induced by vandetanib. Ann Dermatol 2011;23(Suppl 3): 2005;46:714-717. https://doi.org/10.5021/ad.2018.30.4.483 Schnitzler Syndrome: A Case Report and Review of Literature Yoon Seob Kim, Yu Mee Song, Chul Hwan Bang, Hyun-Min Seo, Ji Hyun Lee, Young Min Park, Jun Young Lee Department of Dermatology, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea Dear Editor: Associated symptoms were musculoskeletal pain, and Schnitzler syndrome (SchS) is a rare autoinflammatory dis- bouts of fever. Laboratory investigations showed leukocy- ease characterized by a recurrent urticaria and mono- tosis (10.57×109/L), an elevated erythrocyte sedimen- clonal gammopathy1. Herein, to our knowledge, we re- tation rate (77 mm/hr; 0∼20 mm/hr) and an increased C-re- port the first case of SchS in Korea. The study protocol was active protein (CRP) level (11.95 mg/L; 0.01∼0.47 mg/L). approved by the Institutional Review Board of Seoul St. Increased immunoglobulin (Ig)M levels (852 mg/dL; 46∼ Mary’s Hospital, The Catholic University of Korea 260 mg/dL), decreased IgG (831 mg/dL; 870∼1,700 (KC16ZISE0262). mg/dL) and IgA (99 mg/dL; 110∼410 mg/dL) were A 64-year-old man presented with two year history of dai- detected.
    [Show full text]
  • Beneficial Response to Anakinra and Thalidomide in Schnitzler's Syndrome
    ARD Online First, published on August 11, 2005 as 10.1136/ard.2005.045245 Ann Rheum Dis: first published as 10.1136/ard.2005.045245 on 11 August 2005. Downloaded from Beneficial response to anakinra and thalidomide in Schnitzler’s syndrome Heleen D. de Koning, Evelien J. Bodar, MD, Anna Simon, MD PhD*, Jeroen C.H. van der Hilst, MD, Mihai G. Netea, MD PhD, Jos W.M. van der Meer, MD PhD Department of General Internal Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands *Corresponding author: A. Simon, MD PhD Radboud University Nijmegen Medical Centre Department of General Internal Medicine, 541 PO Box 9101 6500 HB Nijmegen The Netherlands Tel: +31 24 3618819 Fax: +31 24 3541734 Email: [email protected] Word count (excluding abstract and references): 1369 Word count abstract: 140 Category: concise report Short title: Anakinra and thalidomide in Schnitzler’s syndrome http://ard.bmj.com/ on September 28, 2021 by guest. Protected copyright. 1 Copyright Article author (or their employer) 2005. Produced by BMJ Publishing Group Ltd (& EULAR) under licence. Ann Rheum Dis: first published as 10.1136/ard.2005.045245 on 11 August 2005. Downloaded from Abstract Schnitzler’s syndrome is an inflammatory disorder characterised by chronic urticarial rash and monoclonal gammopathy, accompanied by periodic fever, arthralgia or arthritis and bone pain. Etiology and treatment are still enigmatic. Objective: to assess therapy with thalidomide and interleukin-1 receptor antagonist (IL-1ra) anakinra in Schnitzler’s syndrome. Cases: we describe three patients with Schnitzler’s syndrome, one with IgM gammopathy, two with IgG type.
    [Show full text]
  • Chronic Urticaria and Monoclonal Igm Gammopathy (Schnitzler Syndrome) Report of 11 Cases Treated with Pefloxacin
    OBSERVATION Chronic Urticaria and Monoclonal IgM Gammopathy (Schnitzler Syndrome) Report of 11 Cases Treated With Pefloxacin Bouchra Asli, MD; Boris Bienvenu, MD; Florence Cordoliani, MD; Jean-Claude Brouet, MD, PhD; Yurdagul Uzunhan, MD; Bertrand Arnulf, MD; Marion Malphettes, MD; Michel Rybojad, MD; Jean-Paul Fermand, MD Background: Schnitzler syndrome is characterized by duced in 6 patients. In 9 patients, pefloxacin was chronic urticarial rash and monoclonal IgM gammopathy administered for more than 6 months (Յ10 years), with and is sometimes associated with periodic fever, arthral- a good safety profile. gias, and bone pain. Current treatment is unsatisfactory. Conclusions: Pefloxacin therapy can be considered for Observations: Eleven patients with Schnitzler syn- patients with Schnitzler syndrome because it usually im- drome were treated with oral pefloxacin mesylate (800 proves chronic urticaria and the systemic symptoms of mg/d). In 10 patients, we observed a dramatic and sus- the disease. tained improvement of urticarial and systemic manifes- tations. Corticosteroid therapy could be stopped or re- Arch Dermatol. 2007;143(8):1046-1050 HE FEATURES OF SCHNITZ- METHODS ler syndrome include chronic nonpruriginous After the first patient, the drug was proposed to urticaria and monoclonal all patients who were referred to us and ful- IgM gammopathy. Inter- filled the following criteria: (1) recurrent urti- mittentT fever, asthenia, arthralgia, and bone carial rash persisting more than 2 months; pain with imaging evidence of osteoscle- (2) presence of a serum monoclonal IgM; (3) a rosis also occur frequently. Biological find- serum complement level within the reference ings usually include an increase in white range and no detectable cryoglobulinemia; blood cell count and erythrocyte sedimen- (4) no associated systemic disease; and (5) no contraindication to treatment with quinolone tation rate, which reflect an inflamma- agents.
    [Show full text]
  • Schnitzler Syndrome in a Patient with a Family History of Monoclonal
    Volume 24 Number 1 | January 2018 Dermatology Online Journal || Case Report 24 (1): 5 Schnitzler syndrome in a patient with a family history of monoclonal gammopathy Kelly Wilmas1,2 BS, Alexander Aria1,2 BS, Carlos A Torres-Cabala3 MD, Huifang Lu4 MD, Madeleine Duvic2 MD Affiliations: 1University of Texas Health Science Center, McGovern Medical School, Houston, Texas, 2Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, Texas, 3Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, 4Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas Corresponding Author: Kelly Wilmas, University of Texas Health Science Center, McGovern Medical School, 6431 Fannin Street, Houston, Texas, 77030, Tel: (682) 225-4986, Email: [email protected] Abstract [1]. Hepatomegaly and splenomegaly occur less commonly [1]. It is associated with abnormal bone Schnitzler syndrome is a rare disease characterized morphology and inflammatory markers such as by chronic urticaria and a monoclonal gammopathy, an elevated erythrocyte sedimentation rate (ESR), most commonly IgM with light chains of the kappa C-reactive protein (CRP), and leukocytosis [2]. type. There are currently no known risk factors Schnitzler syndrome is thought to be an acquired associated with development of the disease. We report auto-inflammatory disorder mediated by the cytokine a case of Schnitzler syndrome in a 48-year-old man interleukin-1 (IL-1). However, the exact pathogenesis with a family history of monoclonal gammopathies. and link to the monoclonal gammopathy has yet to The patient’s disease has been well controlled with be fully understood [2, 3].
    [Show full text]
  • Mechanisms, Biomarkers and Targets for Adult-Onset Still's Disease
    REVIEWS Mechanisms, biomarkers and targets for adult-onset Still’s disease Eugen Feist1*, Stéphane Mitrovic2,3* and Bruno Fautrel2,4 Abstract | Adult-onset Still’s disease (AoSD) is a rare but clinically well-known, polygenic, systemic autoinflammatory disease. Owing to its sporadic appearance in all adult age groups with potentially severe inflammatory onset accompanied by a broad spectrum of disease manifestation and complications, AoSD is an unsolved challenge for clinicians with limited therapeutic options. This Review provides a comprehensive insight into the complex and heterogeneous nature of AoSD, describing biomarkers of the disease and its progression and the cytokine signalling pathways that contribute to disease. The efficacy and safety of biologic therapeutic options are also discussed, and guidance for treatment decisions is provided. Improving the approach to AoSD in the future will require much closer cooperation between paediatric and adult rheumatologists to establish common diagnostic strategies, treatment targets and goals. Adult-onset Still’s disease (AoSD) was first described macrophages and neutrophils in response to a danger in the early 1970s, by Eric Bywaters1, as an inflam- signal leading to tissue damage. These categories repre- matory condition in young adults. The disease was sent a continuum, which enabled a new classification of similar to childhood-onset Still’s disease (today called immune-mediated inflammatory disorders to be refined systemic-onset juvenile idiopathic arthritis (SoJIA)), in subsequent years3,5. which was described a century ago by Sir John Still2. The diagnosis of autoimmune diseases is often sup- Although the exact pathogenic mechanisms of the ported by the presence of autoantibodies or autoantigen- disease are unknown, substantial advances have specific T cells and B cells.
    [Show full text]
  • VAERS) Standard Operating Procedures for COVID-19 (As of 29 January 2021)
    Vaccine Adverse Event Reporting System (VAERS) Standard Operating Procedures for COVID-19 (as of 29 January 2021) VAERS Team Immunization Safety Office, Division of Healthcare Quality Promotion National Center for Emerging and Zoonotic Infectious Diseases Centers for Disease Control and Prevention 1 Table of Contents Disclaimer 3 Executive Summary 3 1.0 Introduction 3 2.0 VAERS Surveillance Activities 11 2.1 Data processing and coding and follow-up 11 2.1.1 Jurisdiction-specific data in VAERS reports after COVID-19 vaccines 13 2.1.2 Vaccination errors 13 2.2 Automated tables 14 2.2.1 VAERS daily table 14 2.2.2 VAERS weekly tables 14 2.3 Signal detection methods and data analyses 16 2.3.1 Proportional Reporting Ratio (PRR) 16 2.3.2 Data mining 16 2.3.3 Crude reporting rates 17 2.4 Review of VAERS forms and medical records for reports of interest 17 2.5 Signal assessment 19 3.0 Coordination and Collaboration 19 4.0 Appendices 20 4.1 Process of monitoring COVID-19 vaccine adverse events 20 4.2 VAERS codes for different types of COVID-19 vaccine(s) 20 4.3 NURFU (Nurses Follow-up) Guidance, COVID-19 reports 21 4.4 VAERS triaging of reports in business days 27 4.5 Vaccination error groups and MedDRA Preferred Terms (PTs) for COVID-19 vaccination errors 28 4.6: Adverse events of special interest (AESIs) to monitor, and identifying PTs 30 5.0 References 43 2 Disclaimer This document is a draft planning document for internal use by the Centers for Disease Control and Prevention, with collaborating contractors.
    [Show full text]
  • Diagnostic Delay of Schnitzler Syndrome in an Atopic Patient
    Open Access Austin Journal of Allergy A Austin Full Text Article Publishing Group Case Report Diagnostic Delay of Schnitzler Syndrome in an Atopic Patient I Eguíluz-Gracia1*, T Robledo-Echarren1, C Escobar-Bolaños1, R Martínez2, P Villarroel3, M Abstract 1 1 Fernández-Rivas , C Martínez-Cócera Schnitzler syndrome (SS) is a rare auto-inflammatory disorder with 1Allergy Department and IdISSC, Hospital Clínico San recurrent episodes of urticarial rash and fever and monoclonal IgM gammopathy Carlos, Madrid (Spain) as the most common findings. SS has been associated to a high rate of AA 2Hematology Department, Hospital Clínico San Carlos, amyloidosis and lympho-proliferative disorders but not to any other immune Madrid (Spain) mediated disease. We present a 56 year-old woman with respiratory allergy and 3Emergency Unit, Hospital Clínico San Carlos, Madrid pressure urticaria that started to develop episodes of urticarial rashes and fever (Spain) together with diffuse arthralgias. The blood analysis revealed leukocytosis and *Corresponding author: I Eguíluz-Gracia, Hospital monoclonal IgM paraproteinemia. Despite fulfilling criteria for definitive diagnosis Clínico San Carlos, Allergy Department, c/ Prof. Martín of SS, she was not diagnosed and treated with anti-interleukin-1 therapy until Lagos s/n, 28040 Madrid, Spain two years later. The presence of atopic pre-existing conditions might have contributed to this diagnostic delay. With this report we aim to remark that auto- Received: May 27, 2014; Accepted: June 11, 2014; inflammation and allergy can co-exist in the same patient. Published: June 13, 2014 Keywords: Schnitzler syndrome; Allergy; Interleukin 1; Urticaria; Gammopathy What is already known about this topic? stress, she began to present recurrent episodes of less pruritic Schnitzler syndrome (SS) is a rare auto-inflammatory disorder urticarial rashes (UR) with trunk predominance (respecting the face) o with recurrent urticarial rash and fever as clinical hallmarks and followed by abdominal pain and fever up to 39 C.
    [Show full text]